Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial

Name: Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Uploaded: 2023-06-01T02:00:00+00:00
Duration: 3 min 49 s
Description: ESC Heart Failure 2023 Ahmad Masri shares the results of the REDWOOD-HCM Cohort 4 trial, a phase 2 study with aficamten in non-obstructive HCM.

Cardiac myosin inhibitor is safe and effective in HCM in phase trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
ESC Heart Failure 2023
Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Jasper Brugts, MD, PhD
- Jasper Brugts, MD, PhD
Benefits of rapid uptitration of HF medications independent of baseline renal function
Benefits of rapid uptitration of HF medications independent of baseline renal function
ESC Heart Failure 2023
Benefits of rapid uptitration of HF medications independent of baseline renal function
Jozine ter Maaten, MD, PhD
- Jozine ter Maaten, MD, PhD
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
ESC Heart Failure 2023
Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Marianna Fontana, MD, PhD
- Marianna Fontana, MD, PhD
ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
ESC Heart Failure 2023
ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
Robert Mentz, MD
- Robert Mentz, MD

Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial

Recommended

Title